EPISODE · Oct 20, 2023 · 6 MIN
Why experts are criticizing FDA's approach to some neurological drugs
from POLITICO's Pulse Check · host POLITICO
Some experts fear the FDA's accelerated approval process for neurological disease treatments greenlights clinically promising but unproven drugs that can result in giving patients false hope. Host Kelly Hooper talks with POLITICO health care reporter Katherine Ellen Foley about how the FDA is balancing those concerns against the needs of patients. Learn more about your ad choices. Visit megaphone.fm/adchoices
What this episode covers
Some experts fear the FDA's accelerated approval process for neurological disease treatments greenlights clinically promising but unproven drugs that can result in giving patients false hope. Host Kelly Hooper talks with POLITICO health care reporter Katherine Ellen Foley about how the FDA is balancing those concerns against the needs of patients. Learn more about your ad choices. Visit megaphone.fm/adchoices
NOW PLAYING
Why experts are criticizing FDA's approach to some neurological drugs
No transcript for this episode yet
Similar Episodes
Jun 20, 2026 ·2m
Jun 20, 2026 ·2m
Jun 15, 2026 ·3m
Jun 15, 2026 ·3m
Jun 14, 2026 ·2m
Jun 14, 2026 ·2m